LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

Search

Actinium Pharmaceuticals Inc

Geschlossen

1.45 2.11

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.42

Max

1.46

Schlüsselkennzahlen

By Trading Economics

Einkommen

-9.3M

-16M

EPS

-0.51

Angestellte

31

EBITDA

-9.3M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+310.96% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

1. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-624K

48M

Vorheriger Eröffnungskurs

-0.66

Vorheriger Schlusskurs

1.45

Actinium Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Juni 2025, 15:04 UTC

Akquisitionen, Fusionen, Übernahmen

UniCredit's Banco BPM Bid Gets Conditional EU Nod -- Update

19. Juni 2025, 14:33 UTC

Akquisitionen, Fusionen, Übernahmen

UniCredit's Banco BPM Bid Gets Conditional EU Nod

19. Juni 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

19. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

19. Juni 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

19. Juni 2025, 20:38 UTC

Akquisitionen, Fusionen, Übernahmen

Home Depot Bid Kicks Off a Battle for $5 Billion Building-Products Company -- WSJ

19. Juni 2025, 20:38 UTC

Akquisitionen, Fusionen, Übernahmen

Home Depot Privately Made Bid for Building-Products Distributor GMS, Sources Say -- WSJ

19. Juni 2025, 20:38 UTC

Akquisitionen, Fusionen, Übernahmen

Competing Offers Could Prompt Bidding War for GMS, Sources Say -- WSJ

19. Juni 2025, 20:38 UTC

Akquisitionen, Fusionen, Übernahmen

Offer From Home Depot Comes as QXO Makes Unsolicited Proposal at $95.20 Per Share -- WSJ

19. Juni 2025, 17:02 UTC

Akquisitionen, Fusionen, Übernahmen

Worthington Buys Elgen Manufacturing for About $93M, Funded With Cash on Hand

19. Juni 2025, 17:01 UTC

Akquisitionen, Fusionen, Übernahmen

Worthington Enterprises Says Elgen Will Become Part of Its Building Products Segment

19. Juni 2025, 17:01 UTC

Akquisitionen, Fusionen, Übernahmen

Worthington Enterprises Acquires Elgen Manufacturing >WOR

19. Juni 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

19. Juni 2025, 16:20 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

19. Juni 2025, 15:37 UTC

Market Talk

European Gas Soars on Middle East Escalation Fears -- Market Talk

19. Juni 2025, 15:16 UTC

Market Talk

Copper Prices Look Set to Fall Over Third Quarter, Citi Says -- Market Talk

19. Juni 2025, 15:16 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

19. Juni 2025, 15:10 UTC

Market Talk

Dollar Rises as Israel-Iran Conflict Intensifies -- Market Talk

19. Juni 2025, 15:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. Juni 2025, 15:02 UTC

Market Talk

Oil Climbs 2% as Israel-Iran Tensions Mount, With U.S. Role in Focus -- Market Talk

19. Juni 2025, 14:15 UTC

Akquisitionen, Fusionen, Übernahmen

EU: UniCredit Committed to Divest 209 Physical Branches in Overlap Areas Across Italy

19. Juni 2025, 14:15 UTC

Akquisitionen, Fusionen, Übernahmen

EU: UniCredit Commitments Fully Address Competition Concerns Identified

19. Juni 2025, 14:15 UTC

Akquisitionen, Fusionen, Übernahmen

EU Rejected Request From Italian Competition Authority to Refer Deal for National Review

19. Juni 2025, 14:15 UTC

Akquisitionen, Fusionen, Übernahmen

EU Approves UniCredit's Acquisition of Banco BPM, Subject to Conditions

19. Juni 2025, 14:15 UTC

Akquisitionen, Fusionen, Übernahmen

EU Says There Are No Compelling Reasons to Justify Referral to Italy

19. Juni 2025, 13:58 UTC

Market Talk

Market Talk Roundup: BOE Holds Rates as Focus Turns to Likely August Cut

19. Juni 2025, 13:58 UTC

Market Talk

Market Talk Roundup: BOE Holds Rates as Focus -2-

19. Juni 2025, 13:38 UTC

Market Talk

Canadian Small Firms Appear to Be Coping With Tariffs -- Market Talk

19. Juni 2025, 13:33 UTC

Market Talk

BOE Likely to Cut Rates If Firms' Pricing Power Weakens -- Market Talk

19. Juni 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Actinium Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

310.96% Vorteil

12-Monats-Prognose

Durchschnitt 6 USD  310.96%

Hoch 9 USD

Tief 4 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Actinium Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.